전산화단층촬영 주사시간(Scan Time)이 폐종양운동의 재현성에 미치는 영향 분석

김수산(Su Ssan Kim),하성환(Sung Whan Ha),최은경(Eun Kyung Choi),이병용(Byoung Yong Yi) 대한방사선종양학회 2004 Radiation Oncology Journal Vol.22 No.1

목적: 방사선치료계획용 전산화단층촬영(computerized tomography, 이하 CT) 시 주사시간이 종양피부의 재현성에 미치는 영향을 살펴보고자 하였다. 대상 및 방법:인공호흡기의 환기작용에 의해 세로방향의 왕복 운동을 하는 N자형 모형을 제작하였고, 호흡주기를 T로 하였을 때 주사시간을 상대적으로 각각 0.33, 0.50, 0.67, 0.75, 1.00, 1.33, 그리고 1.53T로 설정하고 CT촬영을 시행하였다. 또한 2002년 3월 19일부터 2002년 5월 21일까지 서울아산병원 방사선종양학과에서 정위방사선수술(stereotactic radiosurgery)을 시행받는 비소세포성 폐암 환자 3명을 대상으로, 주사시간이 빠른 CT(LightSpeed, GE Medical Systems, 주사기간 0.8초)와 느린 CT(IQ Premier, Picker, 주사시간 2.0초)mf 각각 1~4회 시행하였다. 각각의 slice에서, N자형 모형의 왕복 운동이 CT영상에 반영된 좌우방향 선분의 길이를 측정하여 치료계획용 CT 촬영이 모형의 움직임을 반영하는 정도를 측정하였다. 환자를 대상으로 한 연구에서는 정위적 체부 고정틀을 이용하여, 빠른 CT 및 느린 CT의 종양을 하나의 CT 영상조합에서 재구성하여 종양의 체적과 장경을 측정하여 비교하였다. 결과: 모형실험에서 주사시간에 비례하여, 세로방향 운동을 CT 촬영에서 반영하는 정도는 증가하였으며 1.00 T 이상에서는 일정한 양상을 보였다. 주사시간 1.00T이상에서 얻어진 결과를 기준으로, 1.00T 미만의 주사시간을 가지는 CT 촬영에서 모형운동을 반영하지 못하는 비율이 각각 0.33T;30%, 0.05T;27%, 0.67T;20%, 0.75T;7.0%로 측정되었다. 또한 투시검사로 측정한 종양의 세로 방향 움직임이 각각 3mm, 5mm, 10mm이었던 각각의 환자에서 느린 CT에서 얻어진 종양의 세로방향 장경이 빠른 CT에 비해 5.3%, 17%, 23% 증가하였다. 결론: 주사시간을 환자의 호흡주기 이상으로 하는 경우 setup margin만을 고려하여 계획용표적체적(planning target volume, PTV)을 정의할 수 있으므로 정상 폐조직에 조사되는 방사선량을 줄여 치료효율을 향상시킬 수 있을 것으로 생각된다. Purpose: To evaluate the reflection of tumor motion according to the planning CT scan time. Material and Methods: A model of N-shape, which moved along the longitudinal axis during the ventilation caused by a mechanical ventilator, was produced. The model was scanned by planning CT, while setting the relative CT scan time (T; CT scan time/ventilatory period) to 0.33, 0.50, 0.67, 0.75, 1.00, 1.33 T, and 1.53 T. In addition, three patients with non-small cell lung cancer who received stereotactic radiosurgery in the Department of Radiation ncology, Asan Medical Center from 03/19/2002 to 05/21/2002 were scanned. Slow (IQ Premier, Picker, scan time 2.0 seconds per slice) and fast CT scans (LightSpeed, GE Medical Systems, with a scan time of 0.8 second per slice) were performed for each patient. The magnitude of reflected movement of the N-shaped model was evaluated by measuring the transverse length, which reflected the movement of the declined bar of the model at each slice. For patients' scans, all CT data sets were registered using a stereotactic body frame scale with the gross tumor volumes delineated in one CT image set. The volume and three-dimensional diameter of the gross tumor volume were measured and analyzed between the slow and fast CT scans. Result: The reflection degree of longitudinal movement of the model increased in proportion to the relative CT scan times below 1.00 T, but remained constant above 1.00 T. Assuming the mean value of scanned transverse lengths with CT scan time 1.00 T to be 100%, CT scans with scan times of 0.33, 0.50, 0.67, and 0.75 T missed the tumor motion by 30, 27, 20, and 7.0% respectively. Slow (scan time 2.0 sec) and Fast (scan time 0.8 sec) CT scans of three patients with longitudinal movement of 3, 5, and 10 mm measured by fluoroscopy revealed the increases in the diameter along the longitudinal axis increased by 6.3, 17, and 23% in the slow CT scans. Conclusion: As the relative CT scan time increased, the reflection of the respiratory tumor movement on planning CT also increased, but remained constant with relative CT scan times above 1.00 T. When setting the planning CT scan time above one respiration period ( 1.00 T), only the set-up margin is needed to delineate the planning target volume. Therefore, therapeutic ratio can be increased by reducing the radiation dose delivered to normal lung tissue.

[紹介] `90년형 FAMILY 소개

쌍용자동차(주) 제품설계실(Product Engineering Dept. Ssan) 한국자동차공학회 1990 오토저널 Vol.12 No.4

Treatment results of breast cancer patients with locoregional recurrence after mastectomy

Yuri Jeong,Su Ssan Kim,Gyungyub Gong,Hee Jin Lee,Sei Hyun Ahn,Byung Ho Son,Jong Won Lee,Eun Kyung Choi,Sang-wook Lee,Ji Hyeon Joo,Seung Do Ahn 대한방사선종양학회 2013 Radiation Oncology Journal Vol.31 No.3

Purpose: To analyze the results of locoregional and systemic therapy in the breast cancer patients with locoregional recurrence (LRR) after mastectomy. Materials and Methods: Seventy-one patients who received radiotherapy for isolated LRR after mastectomy between January 1999 and December 2009 were retrospectively reviewed. Among the 71 patients, 59 (83.1%) underwent wide excision and radiotherapy and 12 (16.9%) received radiotherapy alone. Adjuvant hormonal therapy was given to 45 patients (63.4%). Oncologic outcomes including locoregional recurrence-free survival, disease-free survival (DFS), and overall survival (OS) and prognostic factors were analyzed. Results: Median follow-up time was 49.2 months. Of the 71 patients, 5 (7%) experienced second isolated LRR, and 40 (56%) underwent distant metastasis (DM). The median DFS was 35.6 months, and the 3- and 5-year DFS were 49.1% and 28.6%, respectively. The median OS was 86.7 months, and the 5-year OS was 62.3%. Patients who received hormone therapy together showed better 5-year DFS and OS than the patients treated with locoregional therapy only (31.6% vs. 22.1%, p = 0.036; 66.5% vs. 55.2%, p = 0.022). In multivariate analysis, higher N stage at recurrence was a significant prognostic factor for DFS and OS. Disease free interval (≤30 months vs. >30 months) from mastectomy to LRR was also significant for OS. The patients who received hormone therapy showed superior DFS and showed trend to better OS. Conclusion: DM was a major pattern of failure after the treatment of LRR after mastectomy. The role of systemic treatment for LRR after mastectomy should be investigated at prospective trials.

Safety and efficacy of 10-fraction hypofractionated radiation therapy for non-small cell lung cancer

Ye Jin Yoo,Su Ssan Kim,Si Yeol Song,Jong Hoon Kim,Seung Do Ahn,Sang-wook Lee,Sang Min Yoon,Young Seok Kim,Jin-hong Park,Jinhong Jung,Eun Kyung Choi 대한방사선종양학회 2021 Radiation Oncology Journal Vol.39 No.3

Purpose: To investigate the safety and efficacy of hypofractionated radiation therapy (HFRT) in patients with non-small cell lung cancer who are unfit for surgery or stereotactic body radiation therapy (SBRT) at our institution. Materials and Methods: From May 2007 to December 2018, HFRT was used to treat 68 lesions in 64 patients who were unsuitable for SBRT because of central tumor location, large tumor size, or contiguity with the chest wall. The HFRT schedule included a dose of 50–70 Gy delivered in 10 fractions over 2 weeks. The primary outcome was freedom from local progression (FFLP), and the secondary endpoints included overall survival (OS), disease-free survival, and toxicities. Results: The median follow-up period was 25.5 months (range, 5.3 to 119.9 months). The FFLP rates were 79.8% and 67.8% at 1 and 2 years, respectively. The OS rates were 82.8% and 64.1% at 1 and 2 years, respectively. A larger planning target volume was associated with lower FFLP (p = 0.023). Dose escalation was not associated with FFLP (p = 0.964). Four patients (6.3%) experienced grade 3–5 pulmonary toxicities. Tumor location, central or peripheral, was not associated with either grade 3 or higher toxicity. Conclusion: HFRT with 50–70 Gy in 10 fractions demonstrated acceptable toxicity; however, the local control rate can be improved compared with the results of SBRT. More studies are required in patients who are unfit for SBRT to investigate the optimal fractionation scheme.

Treatment results of breast cancer patients with locoregional recurrence after mastectomy

Jeong, Yuri,Kim, Su Ssan,Gong, Gyungyub,Lee, Hee Jin,Ahn, Sei Hyun,Son, Byung Ho,Lee, Jong Won,Choi, Eun Kyung,Lee, Sang-Wook,Joo, Ji Hyeon,Ahn, Seung Do The Korean Society for Radiation Oncology 2013 Radiation Oncology Journal Vol.31 No.3

Purpose: To analyze the results of locoregional and systemic therapy in the breast cancer patients with locoregional recurrence (LRR) after mastectomy. Materials and Methods: Seventy-one patients who received radiotherapy for isolated LRR after mastectomy between January 1999 and December 2009 were retrospectively reviewed. Among the 71 patients, 59 (83.1%) underwent wide excision and radiotherapy and 12 (16.9%) received radiotherapy alone. Adjuvant hormonal therapy was given to 45 patients (63.4%). Oncologic outcomes including locoregional recurrence-free survival, disease-free survival (DFS), and overall survival (OS) and prognostic factors were analyzed. Results: Median follow-up time was 49.2 months. Of the 71 patients, 5 (7%) experienced second isolated LRR, and 40 (56%) underwent distant metastasis (DM). The median DFS was 35.6 months, and the 3- and 5-year DFS were 49.1% and 28.6%, respectively. The median OS was 86.7 months, and the 5-year OS was 62.3%. Patients who received hormone therapy together showed better 5-year DFS and OS than the patients treated with locoregional therapy only (31.6% vs. 22.1%, p = 0.036; 66.5% vs. 55.2%, p = 0.022). In multivariate analysis, higher N stage at recurrence was a significant prognostic factor for DFS and OS. Disease free interval (${\leq}30$ months vs. >30 months) from mastectomy to LRR was also significant for OS. The patients who received hormone therapy showed superior DFS and showed trend to better OS. Conclusion: DM was a major pattern of failure after the treatment of LRR after mastectomy. The role of systemic treatment for LRR after mastectomy should be investigated at prospective trials.

Salvage radiation therapy for postoperative locoregionally recurrent non-small cell lung cancer: a single-center experience

Yoon Young Jo,Su Ssan Kim,Si Yeol Song,Eun Kyung Choi 대한방사선종양학회 2021 Radiation Oncology Journal Vol.39 No.3

Purpose: To determine the effectiveness of salvage radiation therapy (RT) in patients with locoregional recurrence (LRR) following initial curative resection of non-small cell lung cancer (NSCLC) and identify the prognostic factors affecting survival. Materials and Methods: Between January 2009 and January 2019, 54 patients with LRR after NSCLC surgery were treated with salvage RT (83.3%) or concurrent chemoradiation therapy (16.7%). Twenty-three (42.6%), 21 (38.9%), and 10 (18.5%) patients had local, regional, and both recurrences, respectively. The median RT dose was 66 Gy (range, 37.5 to 70 Gy). The radiation target volume included recurrent lesions with or without regional lymphatics depending on the location and recurrence type. Results: The median follow-up time from the start of RT was 28.3 months (range, 2.4 to 112.4 months) and disease-free interval (DFI) from surgery to recurrence was 21.0 months (range, 0.5 to 92.3 months). Tumor response after RT was complete response, partial response, stable disease, and progressive disease in 17, 29, 5, and 3 patients, respectively. The rates of freedom from local progression at 1 and 2 years were 77.2% and 66.0%, respectively. The median survival duration after RT was 24.8 months, and the 2-year overall survival (OS) rate was 51.1%. On univariate analysis, initial stage, recurrence site, DFI, and tumor response after RT were significant prognostic factors for OS. DFI ≥12 months and tumor response after RT were statistically significant factors on multivariate Cox analysis for OS. Conclusion: Our results demonstrated the effectiveness of salvage RT for LRR of NSCLC following curative surgery.

Postoperative radiation therapy following the incomplete resection of a non-small cell lung cancer

Park, Jaehyeon,Song, Si Yeol,Kim, Su Ssan,Kim, Sang-We,Kim, Woo Sung,Park, Seung-Il,Kim, Dong Kwan,Kim, Yong-Hee,Park, Jongmoo,Lee, Sang-Wook,Kim, Jong Hoon,Ahn, Seung Do,Choi, Eun Kyung The Korean Society for Radiation Oncology 2014 Radiation Oncology Journal Vol.32 No.2

Purpose: To review the results of postoperative radiation therapy (PORT) for residual non-small cell lung cancer (NSCLC) following surgical resection and evaluate multiple clinicopathologic prognostic factors. Materials and Methods: A total of 58 patients, who completed scheduled PORT for positive resection margin, among 658 patients treated with PORT from January 2001 to November 2011 were retrospectively analyzed. Radiation therapy was started at 4 to 6 weeks after surgery. Chemotherapy was also administered to 35 patients, either sequentially or concurrently with PORT. Results: The median age of patients was 63 years (range, 40 to 82 years). The postoperative pathological stage I NSCLC was diagnosed in 10 (17.2%), stage II in 18 (31.0%), and stage III in 30 patients (51.7%). Squamous cell carcinoma was identified in 43, adenocarcinoma in 10, large cell in 1, others in 4 patients. Microscopic residual disease (R1) was diagnosed in 55 patients (94.8%), and the remaining three patients were diagnosed with gross residual disease (R2). The median dose of PORT was 59.4 Gy (range, 50.0 to 64.8 Gy). Chemotherapy was administered to 35 patients (60%), and the median follow-up time was 22.0 months (range, 6.0 to 84.0 months). The 3-year locoregional relapse-free survival and distant metastasis-free survival rates were 82.1% and 52.9%, respectively. The median overall survival was 23.8 months (range, 6.0 to 84.1 months), and the 3-year overall survival rate was 58.2%. Chemotherapy did not influence the failure pattern or survival outcome. Conclusion: PORT is an effective modality for improving local tumor control in incompletely resected NSCLC patients. Major failure pattern was distant metastasis despite chemotherapy.

국소진행성 직장암의 수술 전 동시화학방사선요법의 결과

최상규(Sang Gyu Choi),김수산(Su Ssan Kim),배훈식(Hoon Sik Bae) 대한방사선종양학회 2007 Radiation Oncology Journal Vol.25 No.1

목 적: 국소적으로 진행된 직장암환자에서 수술 전 동시화학방사선요법을 시행한 환자들의 항문 괄약근 보존율과 병기 강하율 등을 분석하고자 후향적 임상 연구를 시행하였다. 대상 및 방법: 2002년 1월부터 2005년 12월까지 조직학적으로 확진된 직장암 환자 중, 병기가 T2 이상이거나 림프절 전이가 있는 환자를 대상으로 하였다. 한림대학교 성심병원 방사선종양학과에서 수술 전 동시화학방사선요법을 시행 받은 36명 중, 본원에서 수술을 시행한 26명을 대상으로 연구를 시행하였다. 환자들은 수술 전 병기결정을 위한 검사를 시행하였고 방사선치료는 CT를 촬영하여 치료계획을 세웠으며 매일 1.8 Gy로 주 5회, 총 방사선 조사량 45.0∼52.2 Gy까지 3차원 방사선치료 방법으로 시행하였으며, 방사선치료 첫째 주와 다섯째 주에 5-FU와 leucovorine을 동시 투여하였다. 수술은 동시화학방사선요법 종료 후 약 2∼4주경에 시행하였다. 결 과: 대상 환자의 연령 중앙값은 61.9세(34∼78)였으며, 남자가 21명, 여자가 5명이었고 추적 관찰 기간의 중앙값은 28개월(11∼44)이었다. 모든 환자에서 절제연 음성인 근치절제가 가능하였으나 병리적으로 완전 반응을 보인 경우는 없었다. 수술은 3예에서 복회음부 절제술을, 나머지 23예에서 하전방절제술이 시행되어 괄약근 보존율은 88.5% (23/26)였다. 수술 후 병기 강하는 12예로 병기 강하율은 46.2%였으며 19예에서 종양 크기가 감소되어 종양 크기 감소율은 73%였다. 국소 재발이 1명, 원격 전이가 3명에서 관찰되었으며 3년 무재발 생존율은 96.7%, 3년 무 전이 생존율은 87%, 그리고 3년 무진행 생존율은 83.1%였다. 치료와 관련된 급성 독성으로는 Grade 3 & 4 빈혈 각각 1예, Grade 3 백혈구 감소증 1예, Grade 3 장폐색 1예가 관찰되었다. 결 론: 직장암 환자들에서 수술 전 동시화학방사선요법은 근치적 수술을 시행한 경우 높은 괄약근보존율과 수술후 병기감소율을 보였으며 치료에 따른 독성도 대부분 경미하고 높은 순응도를 보여 효과적인 방법으로 판단되며 앞으로 많은 환자들을 대상으로 장기간에 걸친 추적 관찰을 요한다. P urpose: We performed a retrospective non- randomized clinical study of locally advanced rectal cancer, to evaluate the anal sphincter preservation rates, down staging rates and survival rates of preoperative chemoradiotherapy. Materials and Methods: From January 2002 to December 2005, patients with pathologically confirmed rectal cancer with clinical stage T2 or higher, or patients with lymph node metastasis were enrolled in this study. A preoperative staging work- up was conducted in 36 patients. All patients were treated with preoperative chemoradiotherapy, and curative resection was performed for 26 patients at Hallym University Sacred Heart Hospital. Radiotherapy treatment planning was conducted with the use of planning CT for all patients. A total dose of 45.0∼52.2 Gy conventionally fractionated three- dimensional radiotherapy was delivered to the whole pelvis. Chemotherapy was given at the first and fifth week of radiation therapy with continuous infusion i.v. 5- FU (Fluorouracil) and LV (Leucovorine). Surgical resection was performed 2 to 4 weeks after the completion of the chemoradiotherapy regimen. R esults: The complete resection rate with negative resection margin was 100% (26/26). However, a pathologically complete response was not seen after curative resection. Surgery was done by LAR (low anterior resection) in 23 patients and APR (abdomino- perineal resection) in 3 patients. The sphincter preservation rate was 88.5% (23/26), down staging of the tumor occurred in 12 patients (46.2%) and down- sizing of the tumor occurred in 19 patients (73%). Local recurrence after surgical resection developed in 1 patient, and distant metastasis developed in 3 patients. The local recurrence free survival rate, distant metastasis free survival rate, and progression free survival rate were 96.7%, 87% and 83.1%, respectively. Treatment related toxicity was minimal except for one grade 3, one grade 4 anemia, one grade 3 leukopenia, and one grade 3 ileus. Conclusion: Preoperative concurrent chmoradiotherapy for locally advanced rectal cancer seems to have some potential benefits: high sphincter preservation and down staging. Treatment related toxicity was minimal and a high compliance with treatment was seen in this study. Further long- term follow- up with a larger group of patients is required

Radiation Pneumonitis in Association with Internal Mammary Node Irradiation in Breast Cancer Patients: An Ancillary Result from the KROG 08-06 Study

최진현,김용배,안성자,이형식,박원,신경환,Su Ssan Kim,김진희,이규찬,김동원,서현석,신현수,서창옥 한국유방암학회 2016 Journal of breast cancer Vol.19 No.3

Purpose: The aim of this study is to present the incidence of radiation pneumonitis (RP) reported within 6 months after treatment for breast cancer with or without internal mammary node irradiation (IMNI). Methods: In the Korean Radiation Oncology Group (KROG) 08-06 phase III randomized trial, patients who were node-positive after surgery were randomly assigned to receive radiotherapy either with or without IMNI. A total of 747 patients were enrolled, and three-dimensional treatment planning with computed tomography simulation was performed for all patients. Of the 747 patients, 722 underwent chest X-rays before and within 6 months after radiotherapy. These 722 patients underwent evaluation, and RP was diagnosed on the basis of chest radiography findings and clinical symptoms. The relationship between the incidence of RP and clinical/dosimetric parameters was analyzed. Results: RP developed in 35 patients (4.8%), including grade 1 RP in 26 patients (3.6%), grade 2 RP in nine patients (1.2%); there was no incidence of grade 3 or higher RP. Grade 2 RP cases were observed in only the IMNI group. The risk of developing RP was influenced by IMNI treatment; pneumonitis occurred in 6.5% of patients (n=23/356) who underwent IMNI and in 3.3% of patients (n=12/366) who did not (p=0.047). The differences in lung dosimetric parameters (mean lung dose, V10–40) were statistically significant between the two groups. Conclusion: IMNI treatment resulted in increased radiation exposure to the lung and a higher rate of RP, but the incidence and severity of RP was minimal and acceptable. This minor impact on morbidity should be balanced with the impact on survival outcome in future analyses.

Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data

Haeyoung Kim,Won Park,Su Ssan Kim,Sung Ja Ahn,Yong Bae Kim,Tae Hyun Kim,Jin Hee Kim,Jin-Hwa Choi,Hae Jin Park,Jee Suk Chang,Doo Ho Choi 대한방사선종양학회 2021 Radiation Oncology Journal Vol.39 No.2

Purpose: This study was conducted to evaluate prognosis of patients with level I/II axillary lymph node metastases from occult breast cancer (OBC). Materials and Methods: Data of 53 patients with OBC who received axillary lymph node dissection (ALND) positive/negative (+/-) breast-conserving surgery between 2001 and 2013 were retrospectively collected at seven hospitals in Korea. The median number of positive lymph nodes (+LNs) was 2. Seventeen patients (32.1%) had >3 +LNs. A total of 48 patients (90.6%) received radiotherapy. Extents of radiotherapy were as follows: whole-breast (WB; n = 11), regional lymph node (RLN; n = 2), and WB plus RLN (n = 35). Results: The median follow-up time was 85 months. Recurrence was found in four patients: two in the breast, one in RLN, and one in the breast and RLN. The 5-year and 7-year disease-free survival (DFS) rates were 96.1% and 93.5%, respectively. Molecular subtype and receipt of breast radiotherapy were significantly associated with DFS. Patients with estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative (ER-/PR-/HER2-) subtype had significantly lower 7-year DFS than those with non-ER-/PR-/HER2- tumor (76.9% vs. 100.0%; p = 0.03). Whole breast irradiation (WBI) was significantly associated with a higher 7-year DFS rate (94.7% for WBI group vs. 83.3% for non-WBI group; p = 0.01). Other factors including patient’s age, number of +LNs, taxane chemotherapy, and RLN irradiation were not associated with DFS. Conclusion: Patients with OBC achieved favorable outcome after ALND and breast-targeting treatment. Molecular subtype and receipt of WBI was significant factors for DFS.